Most DLBCL patients were initially thought to be not amenable to PD-1 blockade since PDL-1/2 alterations are nonfrequent in this disease, and, accordingly, PD-1 blockade therapy has been disappointing to date in R/R DLBCL and FL. Here, PDCD1 is linked to diffuse large B-cell lymphoma.